1440-1843/asset/RESP_left.gif?v=1&s=a110bec2019e1353a37e9b3af15908c01a36bc31)
1440-1843/asset/RESP_right.gif?v=1&s=2996c5a131272e16b9e97c7ece43b33e2548b8e2)
Current clinical trials for the treatment of idiopathic pulmonary fibrosis
Article first published online: 27 DEC 2009
DOI: 10.1111/j.1440-1843.2009.01672.x
© 2010 The Authors. Journal compilation © 2010 Asian Pacific Society of Respirology
Additional Information
How to Cite
KLINGSBERG, R. C., MUTSAERS, S. E. and LASKY, J. A. (2010), Current clinical trials for the treatment of idiopathic pulmonary fibrosis. Respirology, 15: 19–31. doi: 10.1111/j.1440-1843.2009.01672.x
Publication History
- Issue published online: 27 DEC 2009
- Article first published online: 27 DEC 2009
- Received 16 September 2009; invited to revise 29 September 2009; revised 19 October 2009; accepted 21 October 2009.
- Abstract
- Article
- References
- Cited By
Keywords:
- antifibrotic;
- clinical trial;
- idiopathic pulmonary fibrosis;
- therapy;
- trial end-point
ABSTRACT
Most pulmonary consultants are called upon to discuss IPF management with their patients. The gravity of IPF treatment discussion is immense in view of the data that 3- and 5-year mortality rates are approximately 50% and 80%, respectively. Although IPF occurs in older patients with comorbid diseases, most patients with IPF die as a direct consequence of their lung fibrosis. Here, the results of recently completed IPF trials and the rationale for ongoing studies are succinctly reviewed. There are a number of novel agents in clinical trials that are in the earlier stages of development, and there is new evidence supporting palliative therapies, which may help in managing symptoms of IPF, such as cough, without necessarily altering the course of the disease. The information provided herein should facilitate informed physician–patient dialogue.